Baidu
map

BMJ:PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期

2018-11-09 贾朝娟 环球医学

免疫抑制和逃逸是恶性肿瘤细胞的特征之一。程序性细胞死亡1(PD-1)和程序性细胞死亡配体1(PD-L1)轴,不仅在生理免疫平衡中起着关键作用,而且是癌细胞免疫逃逸的一种手段,因此成为有价值的治疗靶点。以PD-1和PD-L1为靶点的抗体的开发和应用,将癌症治疗推入了新纪元。

免疫抑制和逃逸是恶性肿瘤细胞的特征之一。程序性细胞死亡1(PD-1)和程序性细胞死亡配体1(PD-L1)轴,不仅在生理免疫平衡中起着关键作用,而且是癌细胞免疫逃逸的一种手段,因此成为有价值的治疗靶点。以PD-1和PD-L1为靶点的抗体的开发和应用,将癌症治疗推入了新纪元。

PD-1或PD-L1抑制剂对癌症治疗临床实践带来革命性的影响,但目前仅在一小部分患者中观察到稳定的响应和有利的长期结局。患者如果PD-L1表达阴性,将注定不能从抗癌神药中获益了吗?

2018年9月,发表在《BMJ》一项随机对照试验的meta分析,在PD-L1阳性和PD-L1阴性癌症患者中,评估PD-1或PD-L1抑制剂与常规药物的相对疗效。

从PubMed、Embase、Cochrane数据库和美国临床肿瘤学会和欧洲肿瘤内科学会上发表的会议摘要获取数据,截至2018年3月。

研究纳入的PD-1或PD-L1抑制剂相关研究,都有基于PD-L1阳性或阴性的死亡风险比数据。PD-L1阳性或阴性的阈值是,通过免疫组织化学染色方法确定PD-L1染色细胞占肿瘤细胞或肿瘤和免疫细胞总数的1%。

来自8项随机对照试验的4174名晚期或转移性癌症患者被纳入到本研究。

提交

PD-L1阳性和PD-L1阴性患者干预组vs对照组死亡风险比

研究结果显示,同传统药物相比,PD-1或PD-L1抑制剂能明显延长PD-L1阳性(n=2254,风险比0.66)和PD-L1阴性(1920,0.80)患者的总生存期。但是,对于PD-L1阳性和PD-L1阴性患者,PD-1和PD-L1阻断治疗的疗效明显不同(相互作用P=0.02)。

此外,在PD-L1阳性和阴性患者中,不同介入药物、癌症组织型、随机化分层方法、免疫组化评价系统、药物靶点、对照组类型和中位随访时间的患者,PD-1或PD-L1抑制剂均有长期临床获益。

根据8项高质量随机对照试验的公开数据,研究者对4000多名涉及5种晚期实体瘤的患者数据进行了汇总分析。

结果显示,与常规治疗相比,PD-1或PD-L1抑制剂可使PD-L1阳性患者的死亡风险降低34%,使PD-L1阴性患者降低20%。此外,在选定的亚组分析这些生存益处一致。

因此,该研究表明,无论是PD-L1阳性还是阴性患者,PD-1或PD-L1抑制剂治疗都优于常规治疗。

此外,该研究结果表明,不能单独以是否表达PD-L1来确定患者是否适合接受PD-1或PD-L1抑制剂治疗,简单粗暴地将PD-L1阴性患者拒绝在最新科研成果之外。

原始出处:

Shen X and Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018 Sep 10;362:k3529. doi: 10.1136/bmj.k3529.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2019-06-21 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2019-03-22 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2019-02-10 lxg951
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-11 smartjoy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-10 124586e8m31暂无昵称

    温故而知新

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1848641, encodeId=a81b1848641ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Jun 21 22:16:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851831, encodeId=0b2e1851831ea, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Mar 22 08:16:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941500, encodeId=1445194150070, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Feb 10 17:16:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278932, encodeId=da4912e89325d, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378196, encodeId=b62313e81964e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 11 11:16:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352170, encodeId=326f3521e010, content=温故而知新, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Sat Nov 10 13:32:32 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352068, encodeId=e8cf3520687e, content=国内用的还是太少, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a9f2480456, createdName=124586e8m31暂无昵称, createdTime=Fri Nov 09 21:20:18 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-09 124586e8m31暂无昵称

    国内用的还是太少

    0

相关资讯

尺骨低度恶性骨化性纤维黏液样肿瘤伴病理性骨折1例

骨化性纤维黏液样肿瘤是一类组织来源不明确的罕见肿瘤,主要见于成年患者,好发四肢皮下组织或肌肉组织内,少见发生于长骨者。本文报道1例发生于尺骨的骨化性纤维黏液样肿瘤,目的在于提高骨科医师对此类肿瘤的认识。

领航病理实验室精益化管理,助推肿瘤精准医疗快速发展

近年来,世界范围内的肿瘤发病率正急速上升。其中,我国恶性肿瘤发病率约占世界22%,发病人数居全球第一。恶性肿瘤已成为中国人口首要致死原因并造成了沉重的疾病负担。作为公认的肿瘤诊断“金标准”,病理诊断是目前指导临床治疗和预后评估最可靠的依据。图:左起依次为:罗氏诊断中国生命科学和组织诊断部苏忠美总监、复旦大学附属肿瘤医院病理科王坚主任、复旦大学附属肿瘤医院病理科切片室周学科组长、复旦大学附属肿瘤医院

J Virol:科学家发现EB病毒2型能感染人源化小鼠的T淋巴细胞并诱导B淋巴细胞瘤的产生

近日,来自美国的科学家发现EBV能够感染人源化小鼠的T淋巴细胞及诱导B淋巴细胞瘤的产生。该研究成果目前已发表至《Journal of Virology》杂志,题为“Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice”。

CSH 2018:NGS在血液肿瘤临床实践中的思考

随着NGS技术的成熟和临床应用,在分析基因变异方面已成为血液肿瘤诊疗决策的有效工具。以本次会议为例,以基因异常为主题的报告超过20个,是本次CSH的一大“热点”。经过转化医学的沉淀与临床实践积累,NGS技术在哪些方面惠及到临床?NGS对血液肿瘤将来发展带来的帮助是什么?带着这些思考,有幸在2018 CSH会议期间采访到两位领域资深专家:来自浙江大学附属第一医院的金洁教授及来自解放军总医院的于力教授

盘点7大夺命癌症,李咏得的是喉癌?

电视导演哈文在自己的新浪微博上发文称:“在美国,经过17个月的抗癌治疗,2018年10月25日凌晨5点20分,永失我爱..”此后,她的丈夫李咏去世的消息开始引发全网关注,短短数小时,在新浪微博上#李咏去世#、#李咏因癌症去世#的话题阅读量分别高达9.5亿、446万。尽管暂无官方消息透露著名主持人得的是什么癌,但#李咏什么癌#的话题阅读量也有2.2亿。有网友在微博上爆料称,李咏得的是喉癌,在全球顶尖

J Allergy Clin Immunol:一箭双雕!过敏性哮喘和肿瘤的**靶点被发现!

近期,巴西炎症性疾病研究中心(CRID)的研究人员发现了免疫系统中一种常见基因—Blimp-1竟具有“平衡木”作用,当其表达不足时,过敏性哮喘就来敲门,而其一旦过表达,各种肿瘤就蜂拥而至!

Baidu
map
Baidu
map
Baidu
map